{"pmid":32334081,"title":"HEALTH STATUS OF LIVER TRANSPLANTED PATIENTS DURING THE CORONAVIRUS OUTBREAK IN ITALY: A LARGE SINGLE CENTER EXPERIENCE FROM MILAN.","text":["HEALTH STATUS OF LIVER TRANSPLANTED PATIENTS DURING THE CORONAVIRUS OUTBREAK IN ITALY: A LARGE SINGLE CENTER EXPERIENCE FROM MILAN.","Clin Gastroenterol Hepatol","Donato, Maria Francesca","Invernizzi, Federica","Lampertico, Pietro","Rossi, Giorgio","32334081"],"journal":"Clin Gastroenterol Hepatol","authors":["Donato, Maria Francesca","Invernizzi, Federica","Lampertico, Pietro","Rossi, Giorgio"],"date":"2020-04-26T11:00:00Z","year":2020,"_id":"32334081","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.cgh.2020.04.041","keywords":["covid-19","sars-cov-2","immunosuppression","liver transplant recipients"],"source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1665071049744580610,"score":8.518259,"similar":[{"pmid":32298473,"title":"Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement.","text":["Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement.","Coronavirus disease 2019 (COVID-19), the illness caused by the SARS-CoV-2 virus, is rapidly spreading throughout the world. Hospitals and healthcare providers are preparing for the anticipated surge in critically ill patients but few are wholly equipped to manage this new disease. We all must do our part to prepare our patients, clinics, and hospitals for the drastic changes necessary to mitigate the spread of SARS-CoV-2 or we risk overwhelming the capacity of our healthcare system. The goals of this document are to provide data on what is currently known about COVID-19, and how it may impact hepatologists and liver transplant providers and their patients. Our aim is to provide a template for the development of clinical recommendations and policies to mitigate the impact of the COVID-19 pandemic on liver patients and healthcare providers.","Hepatology","Fix, Oren K","Hameed, Bilal","Fontana, Robert J","Kwok, Ryan M","McGuire, Brendan M","Mulligan, David C","Pratt, Daniel S","Russo, Mark W","Schilsky, Michael L","Verna, Elizabeth C","Loomba, Rohit","Cohen, David E","Bezerra, Jorge A","Reddy, K Rajender","Chung, Raymond T","32298473"],"abstract":["Coronavirus disease 2019 (COVID-19), the illness caused by the SARS-CoV-2 virus, is rapidly spreading throughout the world. Hospitals and healthcare providers are preparing for the anticipated surge in critically ill patients but few are wholly equipped to manage this new disease. We all must do our part to prepare our patients, clinics, and hospitals for the drastic changes necessary to mitigate the spread of SARS-CoV-2 or we risk overwhelming the capacity of our healthcare system. The goals of this document are to provide data on what is currently known about COVID-19, and how it may impact hepatologists and liver transplant providers and their patients. Our aim is to provide a template for the development of clinical recommendations and policies to mitigate the impact of the COVID-19 pandemic on liver patients and healthcare providers."],"journal":"Hepatology","authors":["Fix, Oren K","Hameed, Bilal","Fontana, Robert J","Kwok, Ryan M","McGuire, Brendan M","Mulligan, David C","Pratt, Daniel S","Russo, Mark W","Schilsky, Michael L","Verna, Elizabeth C","Loomba, Rohit","Cohen, David E","Bezerra, Jorge A","Reddy, K Rajender","Chung, Raymond T"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32298473","week":"202016|Apr 13 - Apr 19","doi":"10.1002/hep.31281","keywords":["sars-cov-2","cirrhosis","coronavirus","immunosuppression","transplantation"],"source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1664641388228116480,"score":57.12583},{"pmid":32247695,"title":"Uneventful course in IBD patients during SARS-CoV-2 outbreak in northern Italy.","text":["Uneventful course in IBD patients during SARS-CoV-2 outbreak in northern Italy.","Gastroenterology","Norsa, Lorenzo","Indriolo, Amedeo","Sansotta, Naire","Cosimo, Paola","Greco, Salvatore","D'Antiga, Lorenzo","32247695"],"journal":"Gastroenterology","authors":["Norsa, Lorenzo","Indriolo, Amedeo","Sansotta, Naire","Cosimo, Paola","Greco, Salvatore","D'Antiga, Lorenzo"],"date":"2020-04-06T11:00:00Z","year":2020,"_id":"32247695","week":"202015|Apr 06 - Apr 12","doi":"10.1053/j.gastro.2020.03.062","keywords":["covid-19","coronavirus","inflammatory bowel diseases","immunosuppression"],"source":"PubMed","topics":["Prevention"],"weight":1,"locations":["Italy"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"_version_":1664637850764705793,"score":49.83292},{"pmid":32207994,"title":"Critical Organizational Issues for Cardiologists in the COVID-19 Outbreak: A Frontline Experience From Milan, Italy.","text":["Critical Organizational Issues for Cardiologists in the COVID-19 Outbreak: A Frontline Experience From Milan, Italy.","Circulation","Stefanini, Giulio G","Azzolini, Elena","Condorelli, Gianluigi","32207994"],"journal":"Circulation","authors":["Stefanini, Giulio G","Azzolini, Elena","Condorelli, Gianluigi"],"date":"2020-03-26T11:00:00Z","year":2020,"_id":"32207994","week":"202013|Mar 23 - Mar 29","doi":"10.1161/CIRCULATIONAHA.120.047070","source":"PubMed","locations":["Milan","Italy"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Prevention"],"weight":1,"_version_":1663352133743804417,"score":49.784363},{"pmid":32330351,"title":"The impact of the COVID-19 outbreak on Liver Transplantation programmes in Northern Italy.","text":["The impact of the COVID-19 outbreak on Liver Transplantation programmes in Northern Italy.","In January 2020, Novel Coronavirus Disease 2019 (COVID-19) resulted in a global pandemic, creating uncertainty towards the management of Liver Transplantation (LT) programmes. Lombardy has been the most affected region in Italy: The current mortality rate of COVID-19 patients is 18,3% (10022 deaths) (April 10th) with hospitals in Lombardy having to expand the total number of ICU beds from 724 to 1381 to accommodate infected patients. There has been a drastic decrease in liver donors. From February 23(rd) until April 10th, 17 LTs were performed in Lombardy. Mean donor age was 49 years (range 18-74) whereas mean recipient age was 55 (13-69); mean MELD Score was 12 (6-24). All donors underwent screening for SARS CoV-2 prior to LT. Two patients tested positive after LT, and one patient died for COVID on POD 30. 16 patients are alive after an average of 30 days post LT (range 3-46). 10 patients have been discharged. This study has found no specific reason concerning the safety of recipients, to stop liver transplantation programmes. Several Key-lessons from our experience are reported. However, due to the complex circumstances which surround the viral outbreak, the cessation or a reduction in LT activity is a pragmatic requirement.","Am J Transplant","Maggi, Umberto","De Carlis, Luciano","Yiu, Daniel","Colledan, Michele","Regalia, Enrico","Rossi, Giorgio","Angrisani, Marco","Consonni, Dario","Fornoni, Gianluca","Piccolo, Giuseppe","DeFeo, Tullia Maria","32330351"],"abstract":["In January 2020, Novel Coronavirus Disease 2019 (COVID-19) resulted in a global pandemic, creating uncertainty towards the management of Liver Transplantation (LT) programmes. Lombardy has been the most affected region in Italy: The current mortality rate of COVID-19 patients is 18,3% (10022 deaths) (April 10th) with hospitals in Lombardy having to expand the total number of ICU beds from 724 to 1381 to accommodate infected patients. There has been a drastic decrease in liver donors. From February 23(rd) until April 10th, 17 LTs were performed in Lombardy. Mean donor age was 49 years (range 18-74) whereas mean recipient age was 55 (13-69); mean MELD Score was 12 (6-24). All donors underwent screening for SARS CoV-2 prior to LT. Two patients tested positive after LT, and one patient died for COVID on POD 30. 16 patients are alive after an average of 30 days post LT (range 3-46). 10 patients have been discharged. This study has found no specific reason concerning the safety of recipients, to stop liver transplantation programmes. Several Key-lessons from our experience are reported. However, due to the complex circumstances which surround the viral outbreak, the cessation or a reduction in LT activity is a pragmatic requirement."],"journal":"Am J Transplant","authors":["Maggi, Umberto","De Carlis, Luciano","Yiu, Daniel","Colledan, Michele","Regalia, Enrico","Rossi, Giorgio","Angrisani, Marco","Consonni, Dario","Fornoni, Gianluca","Piccolo, Giuseppe","DeFeo, Tullia Maria"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32330351","week":"202017|Apr 20 - Apr 26","doi":"10.1111/ajt.15948","source":"PubMed","topics":["Prevention"],"weight":1,"locations":["Italy","Lombardy","Lombardy","Score"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"_version_":1664996914790137857,"score":48.617085},{"pmid":32335173,"title":"How is immunosuppressive status affecting children and adults in SARS-CoV-2 infection? A systematic review.","text":["How is immunosuppressive status affecting children and adults in SARS-CoV-2 infection? A systematic review.","OBJECTIVES: SARS-CoV-2 infection has now a global resonance. Data on how COVID-19 is affecting immunocompromised patients are however few. With our study we aimed to systematically review the current knowledge on SARS-CoV-2 cases in children and adults with immunosuppression, to evaluate outcomes in this special population. METHODS: A systematic review of literature was carried out to identify relevant articles, searching the EMBASE, Medline, and Google Scholar databases. Studies reporting data on pre-defined outcomes and related to immunosuppressed adults and children with SARS-CoV-2 were included. RESULTS: Sixteen relevant articles were identified with 110 immunosuppressed patients, mostly presenting cancer, along with transplantation and immunodeficiency. Cancer was more often associated with a more severe course, but not necessarily with a bad prognosis. Our data show that both children and adults with immunosuppression seem to have a favorable disease course, as compared to the general population. CONCLUSION: Immunosuppressed patients with COVID-19 seem to be few in relation to the overall figures, and to present a favorable outcome as compared to other comorbidities. This might be explained by a hypothetical protective role of a weaker immune response, determining a milder disease presentation and thus underdiagnosis. Nevertheless, surveillance on this special population should be encouraged.","J Infect","Minotti, Chiara","Tirelli, Francesca","Barbieri, Elisa","Giaquinto, Carlo","Dona, Daniele","32335173"],"abstract":["OBJECTIVES: SARS-CoV-2 infection has now a global resonance. Data on how COVID-19 is affecting immunocompromised patients are however few. With our study we aimed to systematically review the current knowledge on SARS-CoV-2 cases in children and adults with immunosuppression, to evaluate outcomes in this special population. METHODS: A systematic review of literature was carried out to identify relevant articles, searching the EMBASE, Medline, and Google Scholar databases. Studies reporting data on pre-defined outcomes and related to immunosuppressed adults and children with SARS-CoV-2 were included. RESULTS: Sixteen relevant articles were identified with 110 immunosuppressed patients, mostly presenting cancer, along with transplantation and immunodeficiency. Cancer was more often associated with a more severe course, but not necessarily with a bad prognosis. Our data show that both children and adults with immunosuppression seem to have a favorable disease course, as compared to the general population. CONCLUSION: Immunosuppressed patients with COVID-19 seem to be few in relation to the overall figures, and to present a favorable outcome as compared to other comorbidities. This might be explained by a hypothetical protective role of a weaker immune response, determining a milder disease presentation and thus underdiagnosis. Nevertheless, surveillance on this special population should be encouraged."],"journal":"J Infect","authors":["Minotti, Chiara","Tirelli, Francesca","Barbieri, Elisa","Giaquinto, Carlo","Dona, Daniele"],"date":"2020-04-27T11:00:00Z","year":2020,"_id":"32335173","week":"202018|Apr 27 - May 03","doi":"10.1016/j.jinf.2020.04.026","keywords":["adults","cancer","children","immunosuppression","sars-cov-2","transplant"],"source":"PubMed","topics":["Diagnosis","Treatment"],"weight":1,"_version_":1665172302009991168,"score":48.55294}]}